Cargando…
Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation
Many drug–drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to another drug causing inhibition and/or induction of the metabolism or transporter‐mediated disposition of the victim drug. In the worst case, such interactions cause more than tenfold inc...
Autores principales: | Tornio, Aleksi, Filppula, Anne M., Niemi, Mikko, Backman, Janne T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563007/ https://www.ncbi.nlm.nih.gov/pubmed/30916389 http://dx.doi.org/10.1002/cpt.1435 |
Ejemplares similares
-
Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017) -
Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction
por: Tapaninen, Tuija, et al.
Publicado: (2019) -
Placental transporter‐mediated drug interactions and offspring congenital anomalies
por: Ellfolk, Maria, et al.
Publicado: (2020) -
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021) -
Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2021)